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We studied the incidence and progression of coronary artery
calcification in people with early chronic kidney disease.
We used a cohort of 562 adult patients with chronic kidney
disease who had an estimated glomerular filtration rate of
o60ml/min/1.73m2, in a community-based study of people
without clinical cardiovascular disease, the Multi-Ethnic Study
of Atherosclerosis. The majority had stage 3 disease.
Coronary artery calcification was measured at baseline and
again approximately 1.6 or 3.2 years later. The prevalence of
coronary artery calcification at baseline was 66%, and its
adjusted prevalence was 24% lower in African Americans as
compared to Caucasians. The incidence of coronary artery
calcification was 6.1% per year in women and 14.8% in men.
Coronary artery calcification progressed in approximately
17% of subjects per year across all subgroups, and diabetes
was associated with a 65% greater adjusted risk of
progression. Male gender and diabetes were the only factors
associated with adjusted coronary artery calcification
incidence and progression, respectively. Our study shows
that coronary artery calcification is common in people with
stage 3 disease, progresses rapidly, and may contribute to
cardiovascular risk.
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Vascular and soft tissue calcification is common among
individuals with chronic kid ney disease (CKD) and may
represent an important mechanism linking kidney dysfunc-
tion with cardiovascular risk.1–4 Among individuals with
end-stage renal disease, coronary artery calcification (CAC) is
highly prevalent, progresses rapidly, and is associated with
an increased risk of death.1,2,5,6 Even young dialysis patients
with few traditional cardiovascular risk factors have
extensive CAC.7
Among nondialyzed individuals with CKD, the rates of
incidence and progression of CAC are not comprehensively
described. Previous case series describing calcification in
non-dialysis CKD were largely cross-sectional, spanned a
wide range of kidney function, and included relatively few
subjects.3,4,8–12 Therefore, prevalence estimates for coronary
calcification in CKD vary considerably. Previous studies also
included individuals with prevalent cardiovascular disease
who may have already had extensive calcification.
In this descriptive cohort study, we examined the natural
history of CAC in a multiethnic population with predomi-
nantly stage III CKD. Study participants were free of known
clinical cardiovascular disease at baseline, providing an
opportunity to describe the calcification process when it
may be first developing.
RESULTS
Study population
There were 684 Multi-Ethnic Study of Atherosclerosis
(MESA) participants with an estimated glomerular filtration
rate (GFR) of o60ml/min per 1.73m2 at baseline examina-
tion. Among this group, 562 (82%) participants returned for
a follow-up computed tomography (CT) scan (Figure 1).
Compared with returning participants, those who did not
complete follow-up CT scanning were more likely to be
diabetic (27 versus 15%), were African American (29 versus
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18%), and had a modestly lower baseline estimated GFR
(mean 49 versus 52ml/min per 1.73m2). Nonreturning
participants also had higher baseline CAC scores (median 76
versus 28 Agatston units) compared with those who com-
pleted follow-up. Among the 122 nonreturning participants,
19 (16%) died during the follow-up period.
Subsequent analyses were conducted among the 562
participants who completed follow-up CT scans. Among this
study population, 98% had stage III CKD at baseline (median
estimated GFR: 55.4ml/min per 1.73m2; interquartile range:
50.1, 57.3) and 19% had microalbuminuria.
Prevalence of CAC
CAC was present at baseline in 66% of the MESA CKD study
population. Compared with CKD participants without
baseline CAC, CKD participants with prevalent CAC were
older, more likely to be male, had lower HDL-cholesterol
levels, lower estimated GFR, and a modestly greater urine
albumin to creatinine ratio, (Table 1). African-American
participants were significantly less likely to have prevalent
CAC. After adjustment for demographics, diabetes, smoking,
hypertension, body mass index, serum cholesterol levels,
C-reactive protein, cystatin C, and urine albumin-to-creatinine
ratio, African-American race remained statistically associated
with a 24% lower prevalence of CAC (95% CI: 10–36% lower;
P¼ 0.002 for comparison with Caucasians). In contrast, the
adjusted CAC prevalence among Chinese-American, Hispa-
nic, and Caucasian participants with CKD was statistically
indistinguishable. Older age, male sex, hypertension, and
low-density lipoprotein levels were also statistically associated
with a higher prevalence of CAC in the multivariable model.
We questioned whether the lower prevalence of CAC in
African Americans with CKD might have been due to selection
bias caused by the explicit use of race to calculate Modification
of Diet in Renal Disease (MDRD) GFR. To address this
concern, we created a second CKD study population, defined
Subjects with eGFR < 60
N = 684
With follow-up
N = 562
Lost to follow-up
N = 122
No baseline CAC
N = 192
Any baseline CAC
N = 370
Exam 2 follow-up
N = 103
Exam 2 follow-up
N = 201
Exam 3 follow-up
 N = 89
Exam 3 follow-up
 N = 169
Figure 1 | Flow chart of study participation. CAC, coronary
artery calcification; eGFR, estimated glomerular filtration rate.
Table 1 | Baseline characteristics according to prevalent coronary calcification status
All participants
Stratified by presence of calcification
(n=562) No CAC (n=192) Any CAC (n=370) P-value*
Age (years) 68.7 (8.7) 63.9 (8.4) 71.2 (7.9) o0.001*
Male gender 222 (40) 55 (29) 167 (45) o0.001*
Race/ethnicity
Caucasian 306 (54) 100 (52) 206 (56)
Chinese 63 (11) 22 (11) 41 (11)
African American 100 (18) 42 (22) 58 (16)
Hispanic 93 (17) 28 (15) 65 (18) 0.29
BMI (kg/m2) 28.4 (5.3) 28.6 (5.4) 28.3 (5.2) 0.56
Pre-hypertension 72 (13) 29 (15) 43 (12)
Hypertension 400 (71) 110 (57) 291 (78) o0.001*
Family history of MI 240 (47) 78 (44) 162 (48) 0.45
LDL cholesterol (mg per 100ml) 117.7 (32.7) 114.6 (32.5) 119.4 (32.7) 0.10
HDL cholesterol (mg per 100ml) 51.8 (15.1) 54.1 (16.4) 50.6 (14.3) 0.01
Impaired fasting glucose 83 (15) 23 (12) 60 (16)
Diabetes 85 (15) 28 (15) 57 (15) 0.36
Smoking
Never 304 (55) 114 (61) 190 (51)
Ever 207 (37) 58 (31) 149 (40)
Current 45 (8) 16 (9) 29 (8) 0.08
Cystatin C (mg/l) 1.19 (0.42) 1.11 (0.34) 1.24 (0.45) o0.001*
eGFR (ml/min per 1.73m2) 52.2 (7.9) 53.2 (6.8) 51.7 (8.4) 0.02
C-reactive protein (mg/l)a 2.2 (1.0, 4.5) 2.3 (1.1, 5.0) 2.2 (0.9, 4.4) 0.22
Albumin/creatinine (mg/g)a 6.6 (3.6, 17.8) 4.9 (3.1, 10.8) 7.8 (4.0, 23.4) 0.001*
Microalbuminuria 106 (19) 26 (14) 80 (22) 0.02
Serum phosphate (mg per 100ml) 3.53 (0.53) 3.48 (0.57) 3.56 (0.51) 0.17
Serum 25-hydroxyvitamin D (ng/ml) 24.1 (13.9) 22.5 (11.2) 25.0 (15.2) 0.07
BMI, body mass index; CAC, coronary artery calcification; eGFR, estimated glomerular filtration rate; HDL, high-density lipoprotein; LDL, low-density lipoprotein; MI, myocardial
infarction.
aMedian (interquartile range). P-value based on comparison of log-transformed values.
*Statistically significant after Bonferroni’s correction for multiple comparisons.
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by an estimated GFR of o60ml/min per 1.73m2 using
the equation eGFRcystatin¼ 76.7 (cystatin C)1.19, which does
not include race. In this cystatin C-based CKD population,
African-American race was associated with a 27% lower (95%
CI: 11–39%; P¼ 0.001) adjusted prevalence of CAC.
Extent of baseline CAC
Among participants with prevalent calcification at baseline,
the median CAC score was 120 Agatston units (interquartile
range: 31, 377 units; Figure 2). There were 91 participants
with CAC scores between 1 and 30Agatston units. In the fully
adjusted multivariate model, older age, male sex, and higher
C-reactive protein levels were statistically associated with a
greater amount of baseline CAC among participants with
prevalent CAC, whereas African-American race was asso-
ciated with a lower amount of baseline CAC.
Incidence of CAC
The median follow-up time between CT scans was 2.0 years
(interquartile range: 1.5, 3.1). Incident CAC developed in
20% of CKD study participants without baseline CAC
(N¼ 39; estimated incidence rate: 8.5% per year). Incident
CAC was more than twice as common in men than in women
(14.8% per year in men and 6.1% per year in women;
Table 2). In contrast, there were no detectable differences in
incident CAC rates by race/ethnicity. After full adjustment,
male sex was the only characteristic that was associated with a
greater incidence of CAC (Table 2).
Progression of CAC
Among participants with prevalent CAC at baseline, the
median absolute increase in CAC scores was þ 24 Agatston
units per year (intraquartile range: þ 6, þ 66). The extent of
CAC progression was strongly dependent on the baseline
score; higher baseline Agatston scores were associated with
higher absolute and lesser relative changes in CAC during
follow-up (Figure 3). The dichotomous MESA definition of
CAC progression was less dependent on the baseline score
than was either absolute or relative change.
On the basis of the MESA definition of CAC progression,
144 (39%) participants with prevalent CAC progressed
during follow-up, corresponding to an estimated progression
rate of 16.8% per year. CAC progression was not statistically
associated with age, race, or sex (Figure 4). After adjustment,
diabetic participants were B65% more likely to progress
compared with nondiabetic participants (Table 3; 95% CI:
25–118% more likely). Estimated kidney function as defined
by cystatin C levels was not associated with CAC progression.
Substituting serum creatinine level or MDRD estimated GFR
for cystatin C in the multivariate model for CAC progression
did not yield significant results for either variable (P¼ 0.58
for serum creatinine; P¼ 0.60 for MDRD estimated GFR).
DISCUSSION
In a multiethnic cohort with predominantly stage III CKD
and no clinically apparent cardiovascular disease, 66% of
participants had prevalent CAC, confirming a high pre-
valence of subclinical coronary atherosclerosis and/or dys-
trophic calcification in this population. Compared with
Caucasians with CKD, African Americans with CKD had a
24% lower adjusted prevalence of CAC. Incident CAC
developed at a rate of 14.8% per year in men and 6.1% per
year in women. Progression of existing CAC was statistically
similar by race/ethnicity and sex, and was strongly associated
with the presence of diabetes. These data provide population-
based estimates of CAC rates among individuals with CKD
and extend previous findings describing chronic kidney
disease in the MESA population.8,13–15
In previous case series, prevalence estimates for CAC in
CKD vary from 40 to 73%.3,4,9,11,12 For example, Russo et al.4
observed a 40% prevalence of CAC among 85 patients (mean
age: 54 years) with stage III–V CKD who had no known
cardiovascular disease or diabetes. Tomiyama et. al.12
reported a 64% prevalence of CAC among 96 patients (mean
age: 55 years) with an estimated creatinine clearance of
15–90ml/min per 1.73m2 from an outpatient nephrology
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clinic population in Brazil. Qunibi et al.3 reported prevalence
rates of 38 and 73% among 55 Hispanic Americans with
diabetic nephropathy and stages I–II and IV–V CKD,
respectively (mean ages: 52 and 56 years, respectively). Our
prevalence estimate from this somewhat older, relatively
large, multiethnic sample without cardiovascular disease is
within the range of previously reported rates.
Estimates of the prevalence and extent of coronary
calcification observed among patients with an estimated GFR
of o60ml/min per 1.73m2 in this study were similar to
estimates reported among patients with microalbuminuria in
the same MESA population. Kramer et al.16 found an B66%
prevalence of coronary calcification among MESA participants
with microalbuminuria, defined using sex-specific cutoff
points. The distributions of nonzero coronary calcium
scores were also similar comparing microalbuminuria and
estimated GFR ofo60ml/min per 1.73m2 sub-populations in
MESA.
Some previous studies in the general population and in
chronic dialysis patients have also reported a lower
prevalence of CAC among African Americans.17,18 On the
other hand, a recent genetic admixture study conducted in
young adults found no association of African ancestry with
CAC score.19 Possible reasons for ethnic differences in CAC
are unclear, given that CAC could represent atherosclerosis
and/or dystrophic mineralization. Some studies have shown
that compared with Caucasians, African Americans tend to
have higher bone mineral density,20,21 which is inversely
correlated with CAC.22 Given the relatively small number of
African-American participants with CKD in our study, it is
possible that observed differences in the presence and extent
of CAC were due to sampling variation. It is also possible that
African Americans in this study had a shorter duration of
CKD because of a more rapid kidney function decline.
In the general population, the presence and extent of CAC
predicts future cardiovascular events. For example, among
the full 6814-member MESA cohort, CAC scores of 1–100,
101–300, and 4300 were associated with 3.9-, 7.1-, and 6.8-
fold higher risks of incident cardiovascular events, respec-
tively, compared with a CAC score of 0.23 Although CAC may
be less prevalent among African Americans, its existence
more strongly predicts future cardiovascular risk in this race
group. In a general cohort study of 14,812 adults, the
association of CAC score with mortality was more than
twofold higher among African Americans compared with the
non-Hispanic Caucasian reference cohort.24
Coronary calcification in the setting of early CKD may
represent intimal atherosclerosis, medial vessel calcification,
or both. Histological studies of epigastric arteries removed
from chronic dialysis patients have shown evidence of medial
arterial calcification.25 Nontraditional risk factors, such as
higher serum phosphate levels and greater intake of calcium
containing oral phosphorous binders, are associated with
coronary calcification scores in chronic dialysis patients,7,26
suggesting that at least some CAC might represent medial
calcification in advanced kidney failure.27 In stage III CKD,
clinically detectable disturbances in mineral metabolism are
subtle. For example, serum parathyroid hormone levels tend
to be only modestly elevated and serum phosphorous levels
are generally preserved.28 On the other hand, nontradition-
ally measured mineral metabolism markers, such as serum
fibroblast growth factor 23 and urinary phosphorous
excretion, are disturbed early during the course of CKD.29
Whether such factors might contribute to vascular calcifica-
tion in early stages of CKD remains to be tested.
Consistent with previous studies, the baseline CAC score
was the strongest determinant of future calcification.2
Incident CAC developed in only 8.5% of participants
Table 2 | Risk factors for incident coronary artery calcification
Variable Unadjusted IRR (95% CI) Adjusteda IRR (95% CI) Adjustedb IRR (95% CI) P-valuec
Age (1 year older) 1.02 (0.99, 1.05) 1.01 (0.98, 1.04) 1.01 (0.98, 1.05) 0.38
Race/ethnicity
Caucasian Reference Reference Reference
Chinese 1.95 (0.92, 4.14) 2.13 (0.82, 5.50) 2.09 (0.73, 5.98) 0.17
African American 1.45 (0.76, 2.77) 1.05 (0.54, 2.03) 0.84 (0.40, 1.76) 0.64
Hispanic 0.84 (0.31, 2.32) 0.87 (0.31, 2.46) 0.68 (0.24, 1.92) 0.47
Male gender 2.43 (1.43, 4.12) 2.26 (1.32, 3.88) 2.27 (1.26, 4.09) 0.006
Diabetes 1.82 (0.93, 3.55) 1.44 (0.71, 2.92) 1.08 (0.55, 2.14) 0.82
Current smoking 2.03 (1.00, 4.12) 2.05 (1.10, 3.83) 1.66 (0.90, 3.07) 0.11
Hypertension 1.49 (0.84, 2.66) 1.32 (0.70, 2.51) 1.12 (0.56, 2.26) 0.74
Body mass index (1 unit greater) 1.03 (0.98, 1.09) 1.07 (1.00, 1.13) 1.06 (0.99, 1.13) 0.10
LDL cholesterol (10mg per 100ml greater) 1.01 (0.93, 1.10) 1.01 (0.93, 1.10) 1.02 (0.93, 1.11) 0.71
HDL cholesterol (10mg per 100ml greater) 0.87 (0.71, 1.07) 0.98 (0.81, 1.19) 1.03 (0.84, 1.26) 0.76
C-reactive protein (1mg/l greater) 1.00 (0.95, 1.06) 1.01 (0.97, 1.06) 1.00 (0.95, 1.05) 0.95
Cystatin C (0.2mg/l greater) 1.10 (0.98, 1.24) 1.07 (0.93, 1.23) 1.02 (0.87, 1.19) 0.85
Log albumin-to-creatinine ratio 1.22 (1.04, 1.42) 1.16 (0.98, 1.37) 1.11 (0.93, 1.32) 0.24
CI, confidence interval; HDL, high-density lipoprotein; IRR, incidence rate ratio; LDL, low-density lipoprotein.
aAdjusted for age, race, gender, and scanner pair.
bAdjusted for all of the factors in the table plus scanner pair.
cP-value for fully adjusted model.
N= 39 participants with incident coronary calcification.
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annually, and the amount of incident CAC that was detected
was low. Absolute and relative changes in existing CAC
were highly dependent on the extent of baseline CAC,
whereas this dependence was less pronounced using the
MESA definition of CAC progression. Nearly 17% of
individuals with preexisting CAC progressed annually,
when progression was defined as a change that exceeds
the 95% reproducibility limits of the scanner. Individuals
with CKD, who remain persistently noncalcified, represent
an interesting future research opportunity to extend the
understanding of the intrinsic mechanisms that trigger
calcification.
These data have some limitations. Follow-up time was
limited to a median of only 2 years; therefore, results describe
relatively short-term changes in calcification, and are limited
to detecting risk factor associations that exceed the short-
term variability of the scanner. At present, no imaging
method can reliably distinguish intimal calcification, which
represents calcified atherosclerotic plaque, from medial calci-
fication, which represents osseous transformation of vascular
smooth muscle cells that is more specific to individuals with
kidney disease and diabetes. The distinction between
atherosclerosis and medial calcification is important because
therapies for these conditions may differ. The range of kidney
function in this community-based cohort was restricted to
stage III CKD, and findings may differ among individuals
with more advanced CKD. Furthermore, estimating equa-
tions lose precision when estimated GFR values are close
to 60ml/min per 1.73m2.30 Some survival bias due to loss
to follow-up is expected in this longitudinal study of
CAC measurements. Fortunately, mortality between scans
was low. Finally, power to detect separate risk factors
for incidence and progression is limited by the relatively
small number of incident events; however, the initiation
and extension of vascular calcification may represent
different pathophysiological processes, motivating separate
analyses.
The strengths of this study include the community-based,
multiethnic population, the focus on individuals without
clinical cardiovascular disease to evaluate coronary calcifica-
tion when it first develops, and the uniform and precise data
collection methods that were used in MESA. In summary, we
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describe the natural history of CAC in stage III CKD. Future
areas for study include longer term assessment of CAC,
further scrutiny of persistently noncalcified individuals with
CKD, and distinction between atherosclerosis and medial
calcification pathways in nondialysis CKD.
MATERIALS AND METHODS
Study population
We studied participants from the MESA, a multicenter, community-
based study of subclinical cardiovascular disease. Details of the MESA
study design and sampling procedures are described in detail
elsewhere.31 Briefly, MESA investigators recruited 6814 men and
women, 45–84 years old, who identified their race/ethnicity as White/
Caucasian, Black/African American, Chinese, or Spanish/Hispanic/
Latino from six US communities (Baltimore, MD; Chicago, IL;
Forsyth County, NC; Los Angeles, CA; New York, NY; and St Paul,
MN) between July 2000 and August 2002. Individuals were not eligible
for MESA if they had a previous diagnosis of cardiovascular disease
(physician-diagnosed heart attack, angina, stroke, transient ischemic
attack, heart failure, atrial fibrillation, taking nitroglycerin, or having
undergone angioplasty, coronary artery bypass graft, valve replace-
ment, pacemaker or defibrillator implantation, or any surgery on the
heart or arteries). MESA investigators recruited participants according
to prespecified race/ethnicity categories. Each participant provided
informed consent and the Institutional Review Board at each site
approved the study protocol.
For the present analysis, we selected MESA participants who
had CKD at the time of their baseline examination. We defined
CKD by an estimated GFR of o60ml/min per 1.73m2 using the
four-variable MDRD equation.32 MESA laboratory personnel
calibrated serum creatinine levels to the Cleveland Clinic labora-
tory.33 We excluded participants who did not complete a follow-up
CT measurement of coronary calcium (n¼ 122).
Measurement of CAC
MESA field centers measured CAC using electron beam CT or
multidetector row helical CT, as described previously.34 An expert
committee developed protocols to standardize scan acquisition
across the two technologies,34 and data quality was equivalent
between CT scan techniques.35 MESA investigators scanned each
participant twice over phantoms of known physical calcium
concentration, averaged the two scan readings, and scored them
using the Agatston method.36 All scans were read centrally at the
Harbor-UCLA (University of California, Los Angeles) reading
center. Intra-reader variability was 2.8% and inter-reader variability
was 4.1%.34 All MESA participants underwent CT scans for CAC
at their baseline visit. Half of the participants were selected at
random to undergo a repeat scan during the second MESA
examination; the other half underwent repeat scanning during the
third MESA examination. Examinations were conducted an average
of 1.6 and 3.2 years after baseline exam and used identical protocols
as the baseline examination.
Measurement of other study data
MESA participants completed self-administered questionnaires and
provided fasting blood and spot urine samples. Trained MESA
research staff conducted participant interviews and study examina-
tions. We defined diabetes by the use of any diabetes medication, or
a fasting blood glucose level ofX126mg/dl,37 and defined impaired
fasting glucose by a fasting glucose level of 100–125mg/dl in the
absence of diabetes. We defined microalbuminuria by a urinary
albumin-to-creatinine ratio of X30mg/g.33 MESA research staff
obtained three seated blood pressure measurements 5 min apart
using an automated sphygmomanometer, and averaged the last two
measurements for analysis. The Laboratory for Clinical Biochem-
istry Research (University of Vermont, Burlington, VT, USA)
measured serum cystatin C levels using a BNII nephelometer (Dade
Behring Inc., Deerfield, IL, USA).
Statistical analysis
We defined prevalent CAC by a baseline Agatston score 40. This
cutoff point has been used in previous general population studies of
coronary calcification and is relevant to incident cardiovascular
events in MESA.18,38 We defined incident CAC by a follow-
up Agatston score 40 among participants without baseline CAC.
Table 3 | Risk factors for progression of coronary artery calcification
Variable Unadjusted IRR (95% CI) Adjusteda IRR (95% CI) Adjustedb IRR (95% CI) P-valuec
Age (1 year older) 1.00 (0.98, 1.01) 1.00 (0.98, 1.01) 1.00 (0.98, 1.02) 0.79
Race/ethnicity
Caucasian Reference Reference Reference
Chinese 0.67 (0.39, 1.14) 0.82 (0.46, 1.47) 0.74 (0.41, 1.34) 0.33
African American 1.36 (1.03, 1.81) 1.27 (0.94, 1.73) 1.04 (0.75, 1.43) 0.81
Hispanic 1.07 (0.77, 1.48) 1.04 (0.74, 1.47) 0.95 (0.66, 1.38) 0.79
Male gender 1.10 (0.87, 1.39) 1.06 (0.84, 1.35) 1.10 (0.84, 1.42) 0.50
Diabetes 1.77 (1.40, 2.24) 1.69 (1.31, 2.18) 1.65 (1.25, 2.18) o0.001
Current smoking 1.38 (0.99, 1.90) 1.36 (0.96, 1.92) 1.40 (0.95, 2.04) 0.09
Hypertension 1.11 (0.82, 1.50) 1.08 (0.80, 1.47) 0.95 (0.69, 1.33) 0.78
Body mass index (1 unit greater) 1.01 (0.99, 1.04) 1.00 (0.98, 1.03) 1.00 (0.97, 1.02) 0.78
LDL cholesterol (10mg per 100ml greater) 1.01 (0.98, 1.05) 1.01 (0.98, 1.05) 1.01 (0.98, 1.05) 0.39
HDL cholesterol (10mg per 100ml greater) 0.97 (0.90, 1.06) 1.00 (0.92, 1.09) 1.02 (0.94, 1.12) 0.60
C-reactive protein (1mg/l greater) 1.02 (1.00, 1.04) 1.01 (0.99, 1.03) 1.01 (0.98, 1.03) 0.60
Cystatin C (0.2mg/l greater) 1.07 (1.04, 1.09) 1.05 (1.03, 1.08) 1.05 (0.99, 1.12) 0.10
Log albumin-to-creatinine ratio 1.09 (1.02, 1.17) 1.08 (1.01, 1.15) 1.03 (0.95, 1.12) 0.46
CI, confidence interval; BMI, body mass index; HDL, high-density lipoprotein; IRR, incidence rate ratio; LDL, low-density lipoprotein.
aAdjusted for age, race, gender, and scanner pair.
bAdjusted for all of the factors in the table plus scanner pair.
cP-value for fully adjusted model.
N= 144 participants with progression.
996 Kidney International (2009) 76, 991–998
or ig ina l a r t i c l e BR Kestenbaum et al.: Kidney and calcification
A score of 0 indicates two consecutive negative scans, because
calcification scores in MESA were calculated as the mean of two
scans obtained 5min apart.
We examined progression of CAC scores as the absolute and
relative annualized change among participants with a positive
baseline CAC score. We also utilized a dichotomous definition
of CAC progression (yes versus no) that required an absolute change
in CAC that exceeded the 95% repeatability limits of the scanner
(absolute increase in CAC score greater than the expected change
because of measurement error alone). Re-scan limits for CAC were
determined earlier in a repeatability study of the full 6742-member
MESA cohort with repeat scans as follows:39
95% repeatability limit ¼ 0:17  ðbaseline CACÞ
þ 5:00 
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
ðbaseline CACÞ þ 1:08
p
For hypothetical participants with baseline CAC scores of 10, 50,
100, and 400Agatston units, the minimum absolute changes in CAC
required to meet this definition of progression would be 19, 45, 68,
and 169 Agatston units, respectively.
We used Poisson regression with robust variance estimation to
model dichotomous outcomes (CAC prevalence, incidence, and
progression) as a function of predictor covariates. For analyzing the
change in CAC score, we included an offset term for time between
scans and a term for scanner pair to account for equipment
upgrades that occurred between some visits. We used linear
regression to model continuous outcomes such as the extent of
log-transformed baseline Agatston score, the mean absolute change,
and the relative change in the Agatston score. We included a linear
term for time between CT scans in linear regression models. We
adjusted multiple regression models for demographics and tradi-
tional cardiovascular risk factors such as age, race/ethnicity, sex,
diabetes, hypertension, lipids, smoking, body mass index, C-reactive
protein, log urine albumin-to-creatinine ratio, and serum cystatin C.
We conducted statistical analyses using STATA version 9.0 (STATA,
College Station, TX, USA).
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